<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411735</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG018915-01</org_study_id>
    <nct_id>NCT01411735</nct_id>
  </id_info>
  <brief_title>Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure</brief_title>
  <acronym>PIE-I</acronym>
  <official_title>Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure
      and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and
      therapy.

      METHODS: 71 elderly stable, compensated HFPEF patients (age 70+1 years; 80% women) with
      controlled blood pressure were randomized into a 12 month follow-up (FU) double-blind trial
      of enalapril 20 mg per day (E) vs. placebo (P). Assessments included: peak exercise oxygen
      consumption (VO2); six-minute walk test; Minnesota Living with HF Questionnaire (MLHF); MRI;
      Doppler-echocardiography; and vascular ultrasound.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exercise capacity and aortic distensibility</measure>
    <time_frame>9 months</time_frame>
    <description>MRI and expired gas analysis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5mg titrated up to 10mg- twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2.5 mg titrate up to 10mg twice daily placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>2.5mg titrated up to 10mg twice daily</description>
    <arm_group_label>Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2.5mg titrated up to 10mg twice daily.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants will be 60 years of age or older.

        Exclusion Criteria:

          1. systolic dysfunction

          2. patients with evidence of significant ischemic or valvular heart disease

          3. chronic pulmonary disease.

        Participants who appear preliminarily eligible are invited to a formal screening visiting
        with an investigator cardiology physician. They also undergoing a rest and exercise
        electrocardiogram and echocardiogram and pulmonary function testing as well as blood
        hematology and chemistry tests.

        Final eligibility will be based upon all information available at the conclusion of the
        screening visits test, including hospital and outpatient records, history, physical
        examination, echocardiogram and exercise test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalane W Kitzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine-Cardiology Section</affiliation>
  </overall_official>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

